<unk> , sold under the brand name Tukysa, is a small molecule inhibitor of HER2 for the treatment of HER2-positive breast cancer. It was developed by Array BioPharma and licensed to Cascadian Therapeutics (formerly Oncothyreon, subsequently part of Seattle Genetics). Common side effects are diarrhea, palmar-plantar erythrodysesthesia (burning or tingling discomfort in the hands and feet), nausea, fatigue, hepatotoxicity (liver damage), vomiting, stomatitis (inflammation of the mouth and lips), decreased appetite, abdominal pain, headache, anemia and rash. Pregnant or breastfeeding women should not take<unk>  because it may cause harm to a developing fetus or newborn baby.<unk>  was approved for medical use in the United States in April 2020, in Australia in August 2020, and in the European Union in February 2021.
Tucatinib
Neratinib
Fostamatinib
Lapatinib
Ponatinib
Dasatinib
Capmatinib
Pemigatinib